Trillium Therapeutics Inc. Report issue

For profit Phase 1 Phase 2
Founded: Toronto ON Canada (2004)
Status: Acquired by Pfizer (2021)

Organization Overview

First Clinical Trial
2012
NCT01559961
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Trillium Therapeutics Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Merkel Cell (Phase 1)

Cystitis (Phase 1)

Cystitis, Interstitial (Phase 1)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 1)

Mycoses (Phase 1)

Mycosis Fungoides (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Sarcoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 13